In data at the ASCO meeting last week, Grail showed a 1 percent false-positive rate. While that number seems likely to go down, even such a low rate can make a significant difference for patients.
While isatuximab with Celgene's Pomalyst beat Pomalyst with steroid alone, the bigger question is how it will fare on the market versus J&J's Darzalex, which will likely soon be available as an easier-to-use subcutaneous injection.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
It remains unclear how many patients will relapse without the BCMA antigen, which would complicate their ability to use many CAR-T cell therapies later on. However, an expert said the drug's safety could be a challenge.
Only time will tell if a larger Phase III study will confirm data on a few dozen patients, but the two-drug combination appears to produce a higher complete response rate than than an existing doublet combination, without the associated toxicity.
In an interview at the ASCO meeting, BeiGene chief adviser Eric Hedrick said the company is well-prepared for when it likely regains global rights to tislelizumab.
The company presented end-of-Phase I data from the trial, on KTE-X19, at the ASCO meeting in Chicago Saturday.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
The company plans to present early data in a poster on Saturday showing no more than 1 percent of tests generated false-positive results across 12 solid tumor and blood cancers.
In a position statement, ASCO said PBM practices can result in medication dispensing errors, harm physicians' ability to treat patients and drive up costs.
The legislation, which has drawn criticism from researchers, patient advocates and industry, would enable patients to request experimental drugs while bypassing the FDA.
Loxo's data highlight growing industry interest in so-called "basket" trials and drugs that targeted to genetic markers instead of tumor types.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Are portals delivering on their promise to engage patients? Or are these results too often a source of confusion and alarm for patients and the cause of more work for doctors because information is provided with little to no guidance?
“There is a real need to detect cancers that are small [less than 1 cm] before they metastasize. That would be the Holy Grail.”
The market leader in cancer panel gene testing flooded the zone at the annual meeting of the American Society of Clinical Oncology in Chicago.
The American Society of Clinical Oncology‘s effort to use big data and EHRs to earlier detect cancer just got a $1 million boost from pharma giant Bayer Healthcare. The Society, better known as ASCO, recently launched the effort dubbed CancerLinQ with Germany-based SAP, creating what’s described as an IT platform “designed to unlock vast quantities […]
The American Society of Clinical Oncology is teaming up with SAP on an big data initiative that will use EHRs to examine previously inaccessible information that may lead to early identification on potential cancer patients. As part of the effort, eight oncology centers around the country will use CanderLinQ, a health IT platform that will […]